The Wittrup Lab develops protein
engineering technology and applies it to the discovery of new biopharmaceuticals.
In particular, yeast surface display is used for the directed evolution of protein
expression stability, affinity, and specificity. A particular focus is
on the development of anti-cancer drugs, with quantitative studies of cellular-level
pharmacokinetics and pharmacodynamics.
K. Dane Wittrup elected to National Academy of Engineering >>more
Three Adimab antibodies enter human clinical trials >>more
K. Dane Wittrup elected a Fellow of the American Association for the Advancement of Science >>more
"Protein Engineering for Therapeutics A & B", vols. 502 & 503 of Methods in Enzymology, co-edited by K. Dane Wittrup and Greg Verdine, are published >>more